Proactive Investors - Run By Investors For Investors

Shield Therapeutics appoints Karis as chairman

Karis has been on the board for three years already and chairs the remuneration committee

Shield Therapeutics PLC (LON:STX) has appointed James Karis as its new non-executive chairman.

Karis has been on the board for three years already and chairs the remuneration committee.

WATCH: Shield Therapeutics' Feraccru drug 'a potential game-changer'

A 35-year pharma veteran, Karis was chief executive of the privately-held MAPI Group, which was sold to ICON last year.

Former chairman Andrew Heath stood down at this year’s AGM.

Shield’s flagship product Feraccru is going through the process of US approval, with a decision expected by 27 July.

Feraccru has already been approved in Europe as a treatment for iron deficiency in adults.

In a note to clients, analysts at Liberum Capital said: “Mr Karis looks a good appointment given his background and familiarity with the business, particularly ahead of a what is a pivotal year for Shield with head to head data due in the next few months, the potential US approval of Feraccru before the end of July and on-going EU commercialisation.”

Liberum repeated a ‘buy’ rating and 80p price target on Shield Therapeutics’ shares. In afternoon trading, the stock held steady at 35.50p.

 -- Adds analyst comment, share price --

View full STX profile View Profile

Shield Therapeutics PLC Timeline

Related Articles

seeds in a bowl
March 07 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives
February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use